RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
MDM Policy & Practice Thom, H, Hollingworth, W, Sofat, R, Wang, Z, Fang, W, Bodalia, P N, Bryden, P, Davies, P, Caldwell, D, Dias, S, Eaton, D, Higgins, J, Hingorani, A D, Lopez-Lopez, J, Okoli, G, Richards, A, Salisbury, C, Savović, J, Stephens-Boal, A, Sterne, J & Welton, N 2019, ' Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales : Cost-Effectiveness Model and Value of Information Analysis ', MDM Policy & Practice, vol. 4, no. 2 . https://doi.org/10.1177/2381468319866828 MDM Policy & Practice, Vol 4 (2019)
López-López, J A, Sterne, J A C, Thom, H H Z, Higgins, J P T, Hingorani, A D, Okoli, G N, Davies, P A, Bodalia, P N, Bryden, P A, Welton, N J, Hollingworth, W, Caldwell, D M, Savović, J, Dias, S, Salisbury, C, Eaton, D, Stephens-Boal, A & Sofat, R 2017, ' Oral anticoagulants for prevention of stroke in atrial fibrillation : systematic review, network meta-analysis, and cost effectiveness analysis ', BMJ, vol. 359, j5058 . https://doi.org/10.1136/bmj.j5058
ResearcherID Health Technology Assessment, Vol 21, Iss 9 (2017) Sterne, J A, Bodalia, P N, Bryden, P A, Davies, P A, López-López, J A, Okoli, G N, Thom, H H, Caldwell, D M, Dias, S, Eaton, D, Higgins, J P, Hollingworth, W, Salisbury, C, Savović, J, Sofat, R, Stephens-Boal, A, Welton, N J & Hingorani, A D 2017, ' Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation : systematic review, network meta-analysis and cost-effectiveness analysis ', Health Technology Assessment, vol. 21, no. 9, pp. 1-438 . https://doi.org/10.3310/hta21090